Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharma advances on new epilepsy drug trial success

The trial results were described as “very exciting” by medical expert Linda Laux.
Drugs, pills
It follows a separate trial success in March

GW Pharmaceuticals Plc (NASDAQ:GWPH, LON:GWP) rose in Monday’s early deals after the cannabis based medicines company revealed positive results from a Phase 3 trial.

The successful trial was for a potential treatment of Lennox-Gastaut Syndrome, a rare and severe type of childhood onset epilepsy.

In the trial Epidiolex, the drug, was given as an adjunct treatment to patients over a fourteen week period. The drug achieved the trials primary endpoint, which was to show a significant reduction in the monthly frequency of drop seizures compared to a placebo.

The trial results were described as “very exciting” by Linda Laux, who was an investigator for the trial and is director of the Comprehensive Epilepsy Center at the Ann & Robert H. Lurie Children's Hospital of Chicago.

“Lennox-Gastaut syndrome begins in early childhood, is particularly difficult to treat, and the vast majority of patients do not obtain an adequate response from existing therapies,” Laux said.

“These data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures in this highly treatment-resistant population together with an acceptable safety and tolerability profile, which is consistent with my previous clinical experience with Epidiolex.”

The latest breakthrough follows earlier success, in March, of a separate trial using Epidiolex for another Epilepsy condition called Dravet syndrome.

Justin Gover, GW Pharmaceuticals chief executive, said: “We are delighted to announce positive results in this Phase 3 trial of Epidiolex in patients with Lennox-Gastaut syndrome, and particularly pleased that this result is consistent with our recent Phase 3 pivotal data for Epidiolex in Dravet syndrome.

“We believe that this result further demonstrates that Epidiolex offers the potential to be a new effective therapy within the field of treatment-resistant childhood-onset epilepsies.”

Gover said the company was now looking forward to the submission of a new drug application to the US Food and Drugs Administration in the first half of 2017.

In New York, GW Pharmaceutical American Depository Receipts (ADRs) advanced around US$9 or 11% to change hands at US$92.30. Meanwhile, in London, GW shares were up 74p or 14.6% at 580p.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
1537236236_main-better-use.jpg
Tue
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use